RxDoctor Payments Data

Matt Morgan, MD

Allergy & Immunology · Las Vegas, NVNPI 1962403154

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 97.5% of the total across 474 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 34 manufacturers reported payments, led by AstraZeneca at 27.3% of the total. 2025 is the largest year on record at $3,064, 3.5 times the $874 reported in 2019.

$11,886in general payments, 2019–2025

Across 474 payments — averaging $25.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$3K
  • GSK$2K
  • Regeneron Healthcare Solutions, Inc.$1K
  • Pfizer$869
  • Takeda Pharmaceuticals U.S.A., Inc.$801
  • CSL Behring$618
  • plus $3K from 28 others

What the payments were for

  • Consulting fees$951%
  • Food & beverage$11,59098%
  • Education$2012%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few allergy & immunology providers in Nevadato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$53,661
Medicare patients
142
Services billed
4,014

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dupixent SyringeDupilumab43$208,593
Epinephrine11$1,777
Azelastine Hcl64$1,629
Ipratropium Bromide19$1,395
Montelukast Sodium59$425
Doxepin Hcl18$408
Fluticasone Propionate28$274
Prednisone11$30

Paid to pharmacies, not to this prescriber.

Other allergy & immunology in Las Vegas

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →